Results 301 to 310 of about 647,584 (343)

Assessment of ethnic differences in pharmacokinetics and clinical responses of acalabrutinib between Chinese and White patients with B‐cell malignancies

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Aims The aim of this study was to assess differences between Chinese and White patients in pharmacokinetics (PK) of, and clinical response to, acalabrutinib and its pharmacologically active major metabolite, ACP‐5862, to support recommended dosing in Chinese patients with B‐cell malignancies.
Tingting Yao   +5 more
wiley   +1 more source

Liver organoids: From 3D printing to biomedical applications

open access: yesBMEMat, EarlyView.
A comprehensive review on liver organoids culture techniques from 3D printing to organ‐on‐chip, as well as focusing on challenges and perspectives for advancement liver organoids in various future applications. Abstract The liver is an immune organ, especially an immune tolerance organ.
Ying Shi   +4 more
wiley   +1 more source

Engineering antibodies with cancer‐associated binding sites

open access: yesBMEMat, EarlyView.
This review describes antibodies that perform direct/indirect roles in cancer treatment by binding to effective targets and discusses how antibodies kill tumors and modulate tumor microenvironment through these targets. The classification of expression systems for antibody production is summarized to guide appropriate selection based on different ...
Yinqi Tian   +4 more
wiley   +1 more source

Deciphering the skeletal interoceptive circuitry to control bone homeostasis

open access: yesBMEMat, EarlyView.
This review introduces the skeletal interoceptive circuitry, covering the ascending signals from bone tissues to the brain (sensors), the central neural circuits that integrate this information and dispatch commands (CPU), and the descending pathways that regulate bone homeostasis (effectors).
Yefeng Wu   +7 more
wiley   +1 more source

Designing next‐generation immune cell therapies with nanomaterials

open access: yesBMEMat, EarlyView.
Nanomaterials are transforming immune cellular therapies (ICT) by addressing challenges like tumor accessibility and lengthy manufacturing. This perspective highlights innovations such as magnetic nanoparticles for target identification, lipid nanoparticles for T cell stimulation, and nanoparticle‐mediated gene cytokine delivery. These advances promise
Kangfu Chen, Wenhan Wang, Zongjie Wang
wiley   +1 more source

T-lymphocyte subset abnormalities in the Guillain-Barré syndrome

open access: green, 1994
Charlotte Dahle   +2 more
openalex   +1 more source

An open‐label, single‐arm, multicenter, phase II trial of bireociclib as monotherapy for heavily pretreated HR‐positive, HER2‐negative advanced breast cancer patients: BRIGHT‐1 trial

open access: yesCancer Communications, EarlyView.
Abstract Background Bireociclib (XZP‐3287) is a novel selective cyclin‐dependent kinase 4 and 6 (CDK4/6) inhibitor, with a favorable safety profile demonstrated in preclinical and phase I studies. BRIGHT‐1 aimed to further explore the efficacy and safety of bireociclib monotherapy in patients with locally advanced, recurrent or metastatic, hormone ...
Jiayu Wang   +18 more
wiley   +1 more source

Home - About - Disclaimer - Privacy